Kodiak gains as late-stage trial for eye disease candidate meets key goal

Aug. 08, 2022 9:45 AM ETKodiak Sciences Inc. (KOD)REGNBy: Dulan Lokuwithana, SA News Editor

Chart for testing visual acuity, eye drops and anatomical model lies next to inscription Diagnosis Macular Edema. Concept for diagnosis, treatment and prevention of ophthalmic disease Macular Edema

Shidlovski/iStock via Getty Images

The clinical-stage biotech Kodiak Sciences (NASDAQ:KOD) jumped ~15% in the morning hours Monday after the company said its BEACON Phase 3 study for lead asset tedromer met the primary endpoint in patients with macular edema due to retinal vein occlusion.

The global trial involving 568 patients was designed to evaluate tedromer (KSI-301; tarcocimab) against aflibercept, the generic name for Regeneron's (REGN) blockbuster eye disease therapy Eylea.

After two initial monthly loading doses, the trial participants were randomized to receive tarcocimab every two months compared to monthly aflibercept dosing.

The trial reached the primary efficacy endpoint indicating a non-inferior change for tedromer in best-corrected visual acuity (BCVA) score compared to aflibercept, Kodiak (KOD) said.

Despite intraocular inflammation of 1.4% vs. 0.4% for tarcocimab and aflibercept, respectively, the study drug was well tolerated indicating no new safety signals, the company added. The full results from the trial at a medical event in Sep. 2022.

"BEACON is the first study to successfully test a doubling of the treatment interval for anti-VEGF dosing in a pivotal trial in RVO patients," remarked Mark Barakat, a BEACON study investigator. Dr. Barakat is also the Director of the Retinal Research Institute at Retinal Consultants of Arizona.

Insider buying boosted Kodiak (KOD) shares recently amid chatter that the company could become an activist target.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.